Discontinued — last reported Q4 '17
Pultegroup Indefinite-Lived Research and Development Assets decreased by 5.4% to $24.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 43.6%, from $43.94M to $24.80M. Over 3 years (FY 2022 to FY 2025), Indefinite-Lived Research and Development Assets shows a downward trend with a -26.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $66.88M | $64.21M | $61.58M | $58.96M | $56.34M | $53.80M | $51.30M | $48.80M | $46.30M | $43.94M | $41.64M | $39.34M | $26.21M | $24.80M |
| QoQ Change | — | -4.0% | -4.1% | -4.3% | -4.4% | -4.5% | -4.6% | -4.9% | -5.1% | -5.1% | -5.2% | -5.5% | -33.4% | -5.4% |
| YoY Change | — | — | — | — | -15.8% | -16.2% | -16.7% | -17.2% | -17.8% | -18.3% | -18.8% | -19.4% | -43.4% | -43.6% |